Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Average Rating of “Hold” from Analysts

Shares of Hyperion DeFi, Inc. (NASDAQ:HYPD) have been given a consensus rating of “Hold” by the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $4.5833.

A number of equities research analysts have recently commented on the stock. Zacks Research upgraded shares of Hyperion DeFi to a “hold” rating in a research report on Monday, December 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Cantor Fitzgerald began coverage on shares of Hyperion DeFi in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 target price on the stock. Finally, Chardan Capital set a $7.75 price target on Hyperion DeFi and gave the company a “buy” rating in a research report on Wednesday, December 24th.

Insider Buying and Selling

In related news, Director Ellen R. Strahlman bought 11,856 shares of the company’s stock in a transaction on Monday, December 29th. The stock was bought at an average cost of $3.61 per share, for a total transaction of $42,800.16. Following the acquisition, the director directly owned 34,869 shares in the company, valued at $125,877.09. This represents a 51.52% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Happy David Walters purchased 61,930 shares of Hyperion DeFi stock in a transaction dated Wednesday, December 17th. The shares were bought at an average price of $3.02 per share, for a total transaction of $187,028.60. Following the acquisition, the director owned 111,930 shares in the company, valued at approximately $338,028.60. This trade represents a 123.86% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 189,204 shares of company stock valued at $611,467 in the last quarter. Corporate insiders own 10.86% of the company’s stock.

Hedge Funds Weigh In On Hyperion DeFi

Several institutional investors and hedge funds have recently bought and sold shares of HYPD. Sanctuary Advisors LLC purchased a new stake in shares of Hyperion DeFi in the 4th quarter valued at approximately $38,000. Nations Financial Group Inc. IA ADV acquired a new position in Hyperion DeFi in the fourth quarter valued at approximately $40,000. Price T Rowe Associates Inc. MD acquired a new position in Hyperion DeFi in the fourth quarter valued at approximately $73,000. Formidable Asset Management LLC purchased a new position in Hyperion DeFi in the fourth quarter worth approximately $83,000. Finally, State Street Corp acquired a new stake in Hyperion DeFi during the fourth quarter worth $92,000. 25.84% of the stock is currently owned by institutional investors and hedge funds.

Hyperion DeFi Stock Down 9.1%

Shares of HYPD opened at $2.99 on Thursday. The stock has a 50 day moving average price of $3.56 and a 200 day moving average price of $5.82. Hyperion DeFi has a one year low of $0.85 and a one year high of $17.18. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The stock has a market capitalization of $24.43 million, a price-to-earnings ratio of -0.74 and a beta of 2.69.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.